Which of the following monoclonal antibody can be used in Clostridium difficile infection ?
**Core Concept**
Clostridium difficile infection (CDI) is a bacterial infection caused by toxins produced by the bacterium Clostridium difficile. Monoclonal antibodies are being explored as a potential treatment option to neutralize these toxins and mitigate the severity of the infection.
**Why the Correct Answer is Right**
Bezlotoxumab, a monoclonal antibody, targets and binds to the B toxin of C. difficile, preventing it from causing damage to the intestinal lining. This toxin is responsible for the majority of the disease symptoms and complications associated with CDI. By neutralizing the toxin, bezlotoxumab helps to reduce the risk of CDI recurrence and decrease the severity of symptoms in patients who are at high risk of recurrence.
**Why Each Wrong Option is Incorrect**
* **Option A:** No information is available about this monoclonal antibody being used in C. difficile infection.
* **Option B:** No specific monoclonal antibody by this name is known to be used for C. difficile infection.
* **Option D:** No information is available about this monoclonal antibody being used in C. difficile infection.
**Clinical Pearl / High-Yield Fact**
Bezlotoxumab is specifically designed to target the B toxin of C. difficile, and its use has been shown to reduce the risk of CDI recurrence in high-risk patients.
**Correct Answer: C. Bezlotoxumab**